Mirum Pharmaceuticals, Inc. filings document operating results, product-sales disclosures, clinical program updates and governance matters for a rare disease biopharmaceutical company. Its 8-K reports furnish earnings releases, preliminary sales information, Regulation FD investor materials and other event disclosures tied to LIVMARLI, CHOLBAM, CTEXLI and investigational programs such as volixibat and brelovitug.
The company’s SEC record also covers capital-structure and transaction disclosures, including the completed Bluejay Therapeutics acquisition, related pro forma financial information and a PIPE financing. Proxy filings describe annual meeting matters, board elections, executive compensation and equity-plan governance, while registration details identify Mirum common stock as listed on the Nasdaq Global Market under MIRM.
FMR LLC filed a Schedule 13G reporting beneficial ownership of MIRUM PHARMACEUTICALS INC common stock. FMR LLC reports beneficial ownership of 3,777,851.04 shares, representing 6.2% of the class, with sole dispositive power over these shares and no shared voting or dispositive power.
Abigail P. Johnson is also reported as having sole dispositive power over the same 3,777,851.04 shares, likewise representing 6.2% of Mirum’s common stock. One or more other persons may receive dividends or sale proceeds from these securities, but no other person has more than five percent of the total outstanding common stock.
Mirum Pharmaceuticals, Inc. senior vice president and global controller Jolanda Howe sold 1,840 shares of Common Stock on August 3, 2026 at a price of 105.2900 in an open-market or private transaction executed under a Rule 10b5-1 trading plan adopted on March 18, 2026.
After this sale, Howe directly held 1,274.0000 shares of Mirum Common Stock.
Mirum Pharmaceuticals reported strong top-line growth but a much larger loss for the quarter ended June 30, 2026. Product sales, net were $176.2 million for the quarter and $336.1 million for the first half of 2026, compared with $127.8 million and $239.4 million a year earlier.
Loss from operations reached $42.5 million for the quarter and $832.0 million for the first half, driven primarily by $742.7 million of acquired in-process research and development expenses related to the January 2026 Bluejay acquisition and a $16.4 million charge for the Incyte zilurgisertib license. Net loss was $67.2 million for the quarter and $857.4 million year-to-date, or $1.06 and $14.03 per share, respectively.
As of June 30, 2026, Mirum had total assets of $1.04 billion, including $561.3 million of unrestricted cash, cash equivalents and investments, and stated this provides sufficient capital to fund operations for at least twelve months. The company issued $690.0 million of 0.00% convertible senior notes due 2032 and exchanged or repurchased $237.2 million of its 4.00% 2029 notes, leaving $79.0 million principal outstanding. Shares outstanding increased to 64.8 million at June 30, 2026, and stockholders’ equity moved to a deficit of $10.4 million due to the expanded accumulated deficit.
Mirum Pharmaceuticals reported Q2 2026 net product sales of $176.2 million, up from $127.8 million in Q2 2025, and raised 2026 net product sales guidance to $680 million to $700 million. LIVMARLI generated $128.7 million and bile acid medicines $47.5 million, with year-over-year growth of 46% and 20%, respectively.
The company recorded a Q2 net loss of $67,227 (in thousands) as total operating expenses rose to $218.8 million, including $16.4 million of non-recurring acquired in-process R&D associated with a zilurgisertib license and higher R&D and SG&A. Mirum issued $690.0 million of 0.00% convertible senior notes due 2032, settled $237.2 million of 4.00% notes due 2029, and ended June 30, 2026 with unrestricted cash, cash equivalents and investments of $561.3 million.
Pipeline highlights include FDA Breakthrough Therapy and Orphan Drug designations for volixibat in PSC, a pre-NDA meeting where the agency recommended conducting a Phase 3 study with further FDA discussions planned before a potential NDA submission targeted in the first half of 2027, completion of enrollment in the VANTAGE PBC study, and a PDUFA target action date of September 26, 2026 for zilurgisertib in FOP.
A holder of MIRM common stock filed a notice to sell shares through Morgan Stanley Smith Barney LLC Executive Financial Services. The filing lists a proposed sale of 1,840 common shares to be traded on NASDAQ on or after August 3, 2026. It also reports prior sales of 2,721 shares for $326,520.00 on July 1, 2026 and 2,594 shares for $264,458.30 on June 17, 2026 by Jolanda Marie Howe.
Mirum Pharmaceuticals CEO Christopher Peetz exercised stock options for 20,000 shares of common stock at $2.936 per share and sold 20,000 shares in open-market transactions on July 6, 2026 under a Rule 10b5-1 Plan. Following these trades, he holds 196,019 shares directly and 187,500 shares indirectly through The Peetz Family Trust.
Mirum Pharmaceuticals’ chief financial officer Eric Bjerkholt sold 5,000 shares of common stock in open-market transactions. The sales occurred on July 6, 2026 at prices reported between about $121.13 and $124.94 per share, pursuant to a pre-arranged Rule 10b5-1 plan. Following these transactions, he continues to own 42,181 shares directly.
Christopher Peetz submitted a Form 144 reporting a proposed sale of 20,000 shares of Common Stock via a stock option exercise to be executed on 07/06/2026. The filing notes a prior sale of 30,000 shares on 06/01/2026.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice related to 5,000 shares of Common Stock associated with restricted stock dated 09/11/2024. The filing shows a reported sale of 5,000 shares by Eric Bjerkholt on 06/08/2026 with a value listed as $469,073.00.
Mirum Pharmaceuticals SVP and global controller Jolanda Howe reported an open-market sale of 2,721 shares of common stock at $120.00 per share. After the transaction, she directly holds 3,114 shares. The filing notes the sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 18, 2026, indicating it was scheduled in advance rather than timed discretionarily.